Skip to main content

Table 2 Risk factors for osteoporosis and fractures, current comorbidities, and concomitant medications

From: Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)

CharacteristicColombia
(N = 277)
Brazil
(N = 130)
Mexico
(N = 83)
Argentina
(N = 56)
All Patients Latin America Subregion (N = 546)
Maternal history of osteoporosis or hip fracture, n (%)57 (23.4%)37 (40.2%)23 (39.7%)14 (30.4%)131 (29.8%)
Sight problems, n (%)133 (50.6%)84 (68.9%)22 (26.5%)24 (42.9%)263 (50.2%)
Patients experiencing falls in the past year, n (%)103 (38.6%)39 (31.5%)44 (62.9%)18 (34.0%)204 (39.7%)
Number of falls in the past year, n (%)
No falls164 (61.4%)85 (68.5%)26 (37.1%)35 (66.0%)310 (60.3%)
1 fall62 (23.2%)24 (19.4%)14 (20.0%)10 (18.9%)110 (21.4%)
2 falls21 (7.9%)7 (5.6%)9 (12.9%)3 (5.7%)40 (7.8%)
3 or more falls20 (7.5%)8 (6.5%)21 (30.0%)5 (9.4%)54 (10.5%)
Hours of exercise per week, mean (SD)2.6 (8.3)1.2 (1.8)2.1 (2.6)2.0 (2.4)2.1 (6.2)
Use of arms when standing up from a chair, n (%)159 (58.2%)74 (59.2%)57 (68.7%)17 (30.4%)307 (57.2%)
Immobilized for > 12 months, n (%)3 (1.1%)6 (4.8%)1 (1.2%)1 (1.8%)11 (2.1%)
Currently smoking, n (%)16 (5.9%)9 (7.0%)10 (12.0%)4 (7.1%)39 (7.2%)
Alcoholic drinks per week, mean (SD)0.2 (1.2)0.3 (1.1)0.2 (0.8)0.4 (1.9)0.2 (1.2)
Caffeinated drinks per week, mean (SD)8.1 (9.6)11.0 (13.6)7.2 (6.0)3.4 (5.0)8.2 (10.2)
Patients with current comorbidities a, n (%)
Hypertension124 (44.8%)66 (51.2%)37 (44.6%)25 (44.6%)252 (46.2%)
Rheumatoid arthritis or other rheumatologic conditions81 (29.5%)17 (13.4%)19 (22.9%)6 (10.9%)123 (22.8%)
Type 2 diabetes mellitus18 (6.5%)18 (14.3%)8 (9.6%)1 (1.8%)45 (8.3%)
Concomitant medicationsb, n (%)
Antihypertensives83 (30.0%)61 (46.9%)30 (36.1%)17 (30.4%)191 (35.0%)
Thyroid hormones63 (22.7%)18 (13.8%)18 (21.7%)17 (30.4%)116 (21.2%)
Antidepressants15 (5.4%)24 (18.5%)1 (1.2%)3 (5.4%)43 (7.9%)
Insulins/oral hypoglycemics20 (7.2%)14 (10.8%)5 (6.0%)1 (1.8%)40 (7.3%)
Glucocorticoidsc12 (7.5%)7 (8.0%)0 (0.0%)1 (2.9%)20 (6.2%)
  1. N = total number of patients available; n = number of patients with valid (non-missing or unknown) values; SD = standard deviation
  2. aThe three most frequently reported comorbidities in the overall ALAFOS study cohort [10] are listed here
  3. bConcomitant medications related to risk of osteoporosis and falls taken by > 5% of all patients in the overall Latin American subregional cohort at baseline. Other medications included oral anticoagulants/heparin (1.3% of all patients), benzodiazepines (3.8%), antiarrhythmics (4.8%), and anticonvulsants (3.3%)
  4. cDuration of therapy ≥3 months or a prednisone daily equivalent dose ≥7.5 mg
  5. Note: Percentages are calculated using n, the number of valid (not missing or unknown) responses for each item